Cambiar Investors LLC Cuts Stake in Waters Corporation $WAT

Cambiar Investors LLC reduced its position in shares of Waters Corporation (NYSE:WAT – Free Report) by 31.1% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 10,951 shares of the medical instruments supplier’s stock after selling 4,954 shares during the quarter. Cambiar Investors LLC’s holdings in Waters were worth $4,160,000 at the end of the most recent reporting period.

A number of other institutional investors also recently bought and sold shares of WAT. Brighton Jones LLC lifted its position in Waters by 112.9% in the fourth quarter. Brighton Jones LLC now owns 1,269 shares of the medical instruments supplier’s stock worth $471,000 after buying an additional 673 shares during the last quarter. Integrated Wealth Concepts LLC increased its stake in shares of Waters by 2.9% during the first quarter. Integrated Wealth Concepts LLC now owns 1,048 shares of the medical instruments supplier’s stock valued at $386,000 after buying an additional 30 shares during the period. Goldman Sachs Group Inc. increased its stake in shares of Waters by 3.6% during the first quarter. Goldman Sachs Group Inc. now owns 200,051 shares of the medical instruments supplier’s stock valued at $73,733,000 after buying an additional 6,976 shares during the period. Empowered Funds LLC increased its stake in shares of Waters by 16.6% during the first quarter. Empowered Funds LLC now owns 1,126 shares of the medical instruments supplier’s stock valued at $415,000 after buying an additional 160 shares during the period. Finally, Sivia Capital Partners LLC purchased a new position in shares of Waters during the second quarter valued at $232,000. 94.01% of the stock is currently owned by institutional investors.

Waters Trading Up 0.9%

Shares of WAT stock opened at $320.59 on Friday. The company has a debt-to-equity ratio of 0.37, a current ratio of 1.73 and a quick ratio of 1.27. Waters Corporation has a 1-year low of $275.05 and a 1-year high of $414.15. The company has a market cap of $31.45 billion, a price-to-earnings ratio of 29.77, a PEG ratio of 2.03 and a beta of 1.20. The stock has a 50 day simple moving average of $317.20 and a 200-day simple moving average of $351.47.

Waters (NYSE:WAT – Get Free Report) last issued its quarterly earnings results on Monday, February 9th. The medical instruments supplier reported $4.53 EPS for the quarter, topping the consensus estimate of $4.50 by $0.03. Waters had a return on equity of 34.79% and a net margin of 20.30%.The firm had revenue of $932.36 million during the quarter, compared to analysts’ expectations of $928.17 million. During the same period in the previous year, the business earned $4.10 earnings per share. The firm’s revenue for the quarter was up 6.9% on a year-over-year basis. Waters has set its FY 2026 guidance at 14.300-14.500 EPS and its Q1 2026 guidance at 2.250-2.350 EPS. On average, equities research analysts expect that Waters Corporation will post 12.86 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts have issued reports on the company. William Blair assumed coverage on Waters in a research note on Monday, January 5th. They issued an “outperform” rating on the stock. UBS Group lowered their price target on Waters from $395.00 to $370.00 and set a “neutral” rating for the company in a report on Tuesday, February 10th. HSBC began coverage on Waters in a report on Tuesday, January 27th. They set a “buy” rating and a $460.00 target price for the company. Evercore raised Waters from an “in-line” rating to an “outperform” rating and set a $350.00 target price for the company in a report on Monday, April 6th. Finally, Wall Street Zen downgraded Waters from a “buy” rating to a “hold” rating in a report on Sunday, February 8th. Three investment analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating and eight have given a Hold rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $390.44.

Get Our Latest Analysis on WAT

Insider Activity at Waters

In other news, Director Wei Jiang purchased 500 shares of the company’s stock in a transaction that occurred on Monday, March 16th. The stock was purchased at an average cost of $289.46 per share, for a total transaction of $144,730.00. Following the completion of the transaction, the director owned 3,441 shares of the company’s stock, valued at $996,031.86. This trade represents a 17.00% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through the SEC website. Insiders own 0.63% of the company’s stock.

Waters Profile

(Free Report)

Waters Corporation is a global provider of analytical instruments, software and services for laboratory and research applications. The company designs, manufactures and sells technologies centered on liquid chromatography, mass spectrometry, separation science, and related sample preparation and detection systems. Its product portfolio includes chromatographs, mass spectrometers, columns and consumables, laboratory informatics and workflow software, as well as technical support and training services that help customers run and interpret complex analyses.

Waters serves a wide range of end markets that include pharmaceutical and biotechnology companies, contract research and testing laboratories, academic and government research institutions, clinical diagnostics, food and environmental testing, and industrial and chemical manufacturers.

Featured Articles

• Five stocks we like better than Waters

Want to see what other hedge funds are holding WAT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Waters Corporation (NYSE:WAT – Free Report).